In drug development, up to three quarters of toxicity problems are not detected until preclinical or later stages. Cardiotoxicity and hepatotoxicity are common causes of drug safety liabilities and withdrawal of drugs during development.
Relevant. Reliable. Confident.
GE Healthcare develops reagents and other cellular assay products for use in early in vitro screening of drug candidates. Cytiva Cardiomyocytes are derived from NIH-approved human embryonic stem (hES) cells and provide a biologically-relevant alternative to current cell models and primary cells, for predictive toxicity testing.
Phenotype characterized by flow cytometry, subcellular imaging, and electrophysiology.
Functionally verified using patch clamping techniques.
Representative myocyte population comprising ventricular, atrial, and nodal subtypes, the majority being ventricular myocytes.
Karyotype verified produced from undifferentiated hES cells shown to have normal karyotype.
Scalable and available in quantities to match a range of applications
Cryopreserved for ease of use, ready-to-use on thawing, and can be maintained for at least 7 days once recovered into culture.
For in vitro research use only. Not to be used for any therapeutic or diagnostic applications.
back to top >>
|Cytiva Cardiomyocytes form contractile monolayers in culture.
(Click on image to see the beating cardiomyocytes)
|Sarcomeric striations in Cytiva Cardiomyocytes stain positive for cardiac Troponin I (red); nuclei are counterstained with Hoechst 33342 (blue).
||Current-clamp recording from Cytiva Cardiomyocytes shows spontaneous action potentials that are reversibly inhibited by the L-type calcium channel blocker nifedipine.
(Click on image to see the complete graph)
|Hierarchical cluster analysis of data from a high content analysis (HCA) screen can identify and differentiate cardiotoxic compounds on the basis of their distinct multi-parameter signatures.